G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required.

Stable mixed donor/host hematopoietic chimerism can be uniformly established in dogs conditioned with 200 cGy TBI before dog leukocyte antigen (DLA)-identical marrow transplantation and immunosuppressed with a short course of mycophenolate mofetil (MMF) and cyclosporine (CSP) after the transplantation. A further decrease in the TBI dose to 100 cGy or the elimination of MMF in this model results in graft rejection. Here we asked whetherthe addition of G-CSF-mobilized peripheral blood mononuclear cells (G-PBMC) to marrow grafts would enhance donor engraftment in dogs conditioned with 100 cGy TBI and given postgrafting immunosuppression with CSP alone. Using this model, 7 of 9 dogs given only marrow cells rejected their grafts within 8 to 17 weeks after transplantation. In contrast, the addition of unmodified G-PBMC to marrow grafts resulted in stable mixed donor/host chimerism in 5 of 8 dogs studied (P = .06). However, addition of the CD3-depleted fraction of G-PBMC, which contained both CD34 cells and CD14 cells, resulted in engraftment in only 1 of 7 recipients. We conclude that adding G-PBMC to marrow grafts replaced the requirement of MMF and 100 cGy of TBI, and that CD3 cells were required to facilitate engraftment of marrow cells in DLA-identical recipients, whereas the additional CD34 cells present in G-PBMC were not sufficient for this effect.

[1]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[2]  C. Perreault,et al.  Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor , 2000, Bone Marrow Transplantation.

[3]  N. Schmitz,et al.  Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). , 2000, Blood.

[4]  N. Young,et al.  Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. , 2000, Blood.

[5]  J. Bourhis,et al.  Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Lonial,et al.  Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease. , 1999, Blood.

[7]  N. Hensel,et al.  Human G‐CSF‐mobilized CD34‐positive peripheral blood progenitor cells can stimulate allogeneic T‐cell responses: implications for graft rejection in mismatched transplantation , 1999, British journal of haematology.

[8]  M. Álvarez-Mon,et al.  Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response , 1999, British Journal of Cancer.

[9]  J. Talmadge,et al.  Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products , 1999, Bone Marrow Transplantation.

[10]  B. Sandmaier,et al.  The expression and differentiation pattern of cell antigens and adhesion molecules on the nonadherent cell population in canine long-term marrow culture: a biphasic development of myeloid and lymphoid cells. , 2008, Tissue antigens.

[11]  R. Storb,et al.  Canine T cells transduced with a herpes simplex virus thymidine kinase gene: a model to study effects on engraftment and control of graft-versus-host disease. , 1998, Transplantation.

[12]  M. Mielcarek,et al.  Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. , 1998, Blood.

[13]  P. Chrobak,et al.  Non-host-reactive donor CD8+ T cells of Tc2 phenotype potently inhibit marrow graft rejection. , 1998, Blood.

[14]  R. Storb,et al.  Characterization of monoclonal antibodies that recognize canine CD34. , 1998, Blood.

[15]  M. Mielcarek,et al.  Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells. , 1998, Blood.

[16]  S. Strober,et al.  Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. , 1997, Blood.

[17]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.

[18]  R. Negrin,et al.  Granulocyte colony-stimulating factor-induced comobilization of CD4- CD8- T cells and hematopoietic progenitor cells (CD34+) in the blood of normal donors. , 1997, Blood.

[19]  M. Mielcarek,et al.  Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. , 1997, Blood.

[20]  R. Storb,et al.  Molecular analysis of DLA-DRBB1 polymorphism. , 1996, Tissue antigens.

[21]  R. Storb,et al.  Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. , 1996, Blood.

[22]  E. Ostrander,et al.  Histocompatibility testing of dog families with highly polymorphic microsatellite markers. , 1996, Transplantation.

[23]  H. Deeg,et al.  Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors , 1996 .

[24]  J. Ferrara,et al.  Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.

[25]  H. Deeg,et al.  DLA-identical marrow grafts after low-dose total-body irradiation. Addition of viable donor peripheral blood mononuclear cells does not enhance engraftment. , 1995, Transplantation.

[26]  N. Schmitz,et al.  Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) , 1995, Blood.

[27]  Giralt,et al.  Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. , 1995, Blood.

[28]  E. Bryant,et al.  USE OF (CA)n POLYMORPHISMS TO DETERMINE THE ORIGIN OF BLOOD CELLS AFTER ALLOGENEIC CANINE MARROW GRAFTING , 1994, Transplantation.

[29]  P. Martin,et al.  Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans , 1993, The Journal of experimental medicine.

[30]  F. Appelbaum,et al.  STUDIES OF THE USE OF L‐LEUCYL‐L‐LEUCINE METHYL ESTER IN CANINE ALLOGENEIC MARROW TRANSPLANTATION , 1993, Transplantation.

[31]  H. Deeg,et al.  Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. , 1993, International journal of radiation oncology, biology, physics.

[32]  P. Martin The role of donor lymphoid cells in allogeneic marrow engraftment. , 1990, Bone marrow transplantation.

[33]  L. Shaw,et al.  Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. , 1990, Transplantation proceedings.

[34]  T. Lapidot,et al.  Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  L. Shaw,et al.  Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. , 1990, Clinical chemistry.

[36]  W. Ladiges 4 – Experimental Techniques Used to Study the Immune System of Dogs and Other Large Animals , 1989 .

[37]  B. Sandmaier,et al.  L-leucyl-L-leucine methyl ester treatment of canine marrow and peripheral blood cells. Inhibition of proliferative responses with maintenance of the capacity for autologous marrow engraftment. , 1988, Transplantation.

[38]  H. Deeg,et al.  Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. , 1988, Bone marrow transplantation.

[39]  J. Gribben,et al.  Graft rejection following HLA matched T‐lymphocyte depleted bone marrow transplantation , 1986, British journal of haematology.

[40]  J. Heavner Methods of animal experimentation , 1965 .